Evidence map›Paper›PMID 22370911›Full record

ArticleThrombosis and haemostasis2012

Antithrombotic activity of protein S infused without activated protein C in a baboon thrombosis model.

M J Heeb, U Marzec, A Gruber, S R Hanson

Abstract read
In one paragraph

Article in Thrombosis and haemostasis, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

M J HeebDepartment of Molecular and Experimental Medicine, The Scripps Research Institute, 10550 N. Torrey Pines Rd., La Jolla, CA 92037, USA. heeb@scripps.edu
U Marzec
A Gruber
S R Hanson
Oregon Health & Science University · USScripps Research Institute · US

Funding

YR 50 PROJ- ROBERTS PRIMATE ISLETP51RR000163 · NCRR · OREGON REGIONAL PRIMATE RESEARCH CENTER · PI FRUH, KLAUS J · 1985 to 2011
$140.8M
Therapeutic Thrombin AnalogsR44HL095315 · NHLBI · ARONORA, INC. · PI GRUBER, ANDRAS, TUCKER, ERIK IAN · 2009 to 2016
$5.0M
Vascular tissue engineering: rational design using modelingR01HL095474 · NHLBI · OREGON HEALTH & SCIENCE UNIVERSITY · PI HINDS, MONICA T · 2009 to 2012
$2.4M
New Aspects of Protein S Anticoagulant ActivityR01HL088375 · NHLBI · SCRIPPS RESEARCH INSTITUTE, THE · PI HEEB, MARY J · 2008 to 2011
$1.7M
Novel Anticoagulant MechanismsR01HL070002 · NHLBI · SCRIPPS RESEARCH INSTITUTE, THE · PI HEEB, MARY J · 2003 to 2006
$1.5M
REPRODUCTIVE STEROIDS AND EXPERIMENTAL STROKEK01RR000163 · NCRR · OREGON HEALTH AND SCIENCE UNIVERSITY · PI MURPHY, STEPHANIE J · 2000 to 2004
$479k
NCRR NIH HHS K01 RR000163NCRR NIH HHS P51 RR000163NHLBI NIH HHS R01 HL070002NHLBI NIH HHS R01 HL088375NHLBI NIH HHS R01 HL095474NHLBI NIH HHS R44 HL095315
6 · The paper itself

Abstract

Protein S (ProS) is an essential plasma protein that enhances the anticoagulant activity of activated protein C (APC). In vitro , purified native human Zn2+-containing ProS also exerts direct anticoagulant activity by inhibiting prothrombinase and extrinsic FXase activities independently of APC. We investigated antithrombotic effects of ProS infused without APC in a baboon shunt model of thrombogenesis that employs a device consisting of arterial and venous shear flow segments. In in vitro experiments, the Zn2+-containing human ProS used for the studies displayed >10-fold higher prothrombinase inhibitory activity and anticoagulant activity in tissue factor-stimulated plasma, and four-fold higher inhibition of the intrinsic pathway than the Zn2+-deficient ProS used. In the thrombosis model, ProS (33 μg/minute for 1 hour) or saline was infused locally; platelet and fibrin deposition in the shunt were measured over 2 hours. During experiments performed at 50 ml/minute blood flow, Zn2+-containing ProS inhibited platelet deposition 73-96% in arterial-type flow segments and 90-99% in venous-type flow segments; Zn2+-deficient ProS inhibited platelet deposition 52% in arterial-type flow segments and 65-73% in venous-type flow segments. At 100 ml/min blood flow rate, Zn2+-containing ProS inhibited platelet deposition by 39% and 73% in the respective segments; Zn2+-deficient ProS inhibited platelet deposition by 5% and 0% in the respective segments. Zn2+-containing ProS suppressed fibrin deposition by 67-90%. Systemic APC-independent ProS activity was significantly increased and thrombin-antithrombin complex levels were significantly decreased after infusion of ProS. Thus, infused human Zn2+-containing ProS is antithrombotic in primates, and may have therapeutic potential even in protein C-deficient human patients.

Indexed as

AnimalsAnticoagulantsBlood PlateletsCysteine EndopeptidasesDisease Models, AnimalFibrinFibrinolytic AgentsHemostasisHumansMaleNeoplasm ProteinsPapioProtein CProtein C DeficiencyProtein SThrombosisAnticoagulantscancer procoagulantCysteine EndopeptidasesFibrinFibrinolytic AgentsNeoplasm ProteinsProtein CProtein SZinc

Identifiers

PMID22370911
PMCPMC3319843
OpenAlexW2146347940

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.